Developer docs
API playgroundTry for free, no card

Search company profiles

Blue Heron Capital

Full company profile

uuid0003ph2

Namestring
Blue Heron Capital
Legal namestring
Blue Heron Capital
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Blue Heron Capital is a private early-stage growth equity firm headquartered in Richmond, Virginia, founded in 2006 with first disclosed portfolio activity in 2013. The firm invests growth equity and minority positions in healthcare technology and services businesses and select enterprise technology platforms, targeting companies at the $3–$20 million revenue stage with high growth, strong gross margins, capital efficiency, and experienced management teams open to active investor engagement.

The firm's central differentiated product is the OA Collaborative — a network of 45+ Operating Advisors (seasoned entrepreneurs and operating executives) that supplements Blue Heron's 8-person core investment team. This network actively sources deals, contributes diligence, and engages with portfolio companies across strategy, talent, and execution. The OA Collaborative is positioned as "human capital" paired with financial capital and is the firm's primary mechanism for portfolio value creation. Co-founders Tom Benedetti and Andrew Tichenor, each with 30+ years of relevant experience, anchor the firm alongside Operating Partner Jim Riley, who brings a documented track record (5.8x average MOIC across 7 VC/PE-backed companies, $2B cumulative enterprise value at exit).

Blue Heron generates revenue through standard VC economics: management fees on committed and invested capital across at least three successive funds (Fund I, II, III), and carried interest from exits including Verisma (6.9x MOIC, 40% IRR), Stratasan (3.3x MOIC, 53% IRR), STARC Systems (38% CAGR during hold), Avizia (acquired by Amwell), and Amwell (IPO). The firm manages 20+ active and 12+ exited portfolio companies, with deal flow sourced through OA Collaborative referrals, direct CEO relationships, and co-investor networks (Catalyst Investors, Long Ridge, Nuveen, Peterson Partners, Toba Capital, SpringTide, Communitas Capital). Underlying technology is minimal — investor portal and cap table administration run on Carta, with no proprietary investment platform disclosed.

Short descriptiontext

Blue Heron Capital is a Richmond, VA-based private growth equity firm investing minority positions in healthcare and enterprise technology companies at $3–$20 million revenue, pairing financial capital with its 45-member OA Collaborative of operating advisors to actively support portfolio CEOs through exit.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRichmond, United States
HQ citystring
Richmond
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
growth equity investing, venture capital firm, healthcare growth equity, enterprise technology investing, minority equity investments
Product category
Growth Equity / Venture Capital
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees & Carried Interest
TypeManaged Services
Description

As a growth equity / venture capital firm operating multiple funds (Fund I, Fund II, Fund III referenced), Blue Heron Capital generates revenue through typical VC economics: management fees on committed/invested capital across portfolio funds and carried interest on successful exits. Historical exits include Verisma (6.9X MOIC, 40% IRR), Stratasan (3.3X MOIC, 53% IRR), STARC Systems, Avizia (sold to American Well), Verima, Amwell (exited via IPO), and others.

sourcery.vc
2Capital Gains from Portfolio Exits
TypeLicensing Royalties
Description

Returns generated from successful exits of portfolio company investments across healthcare and enterprise technology — including acquisitions by strategic buyers (American Well for Avizia, AdaptHealth for DuraMedic, Spectrum Equity/Rise Fund for PresenceLearning, Brown & Brown for Tricast, NewSpring Capital for Verisma, Syntellis for Stratasan, North Branch Capital for STARC Systems) and IPOs (Amwell).

blueheroncap.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1OA Collaborative
Description

An extensive network of seasoned professionals and successful entrepreneurs (Operating Advisors) who engage with portfolio companies in leadership, insight, and networking to accelerate their growth.

blueheroncap.com
Core offering1 text field

Blue Heron Capital is an early-stage growth equity firm that makes minority investments in healthcare technology and services businesses and select enterprise technology platforms with $3-$20 million in revenue. Each investment is paired with access to the firm's OA Collaborative, a 45+ member network of operating advisors and seasoned entrepreneurs who provide portfolio companies with hands-on mentorship, board representation, sourcing, and strategic guidance. The firm manages multiple successive funds (Fund I, Fund II, Fund III) that deploy capital via typical VC economics of management fees and carried interest.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 5.8x average MOIC across 7 VC/PE-backed companies Jim Riley was involved with
+4 more records
Product overview1 text field

Blue Heron Capital operates a single integrated service platform centered on early-stage growth equity investing combined with its proprietary OA Collaborative support program. The Growth Equity Investment Program constitutes the core offering, investing in healthcare (technology-based and services businesses addressing cost containment, patient experience, better care, technology innovation, and aging in place) and enterprise technology (B2B platforms with high switching costs, attractive growth, scalable technology, and potential healthcare applications). The OA Collaborative is the differentiated value-add layer that wraps every investment: an in-house network of operating advisors and seasoned entrepreneurs providing hands-on mentorship, market insight, sourcing, board representation, and strategic guidance to portfolio CEOs across the investment life cycle. Blue Heron Fund III is the current fund vehicle that deploys capital sourced through this platform. Together, these two elements (capital + human capital OA Collaborative) form a unified platform-plus-services architecture rather than a modular software product.

Product and service4 records
1Growth Equity Investment Program
CategoryCore Investment Service
Description

Early-stage growth equity investment program targeting healthcare and select enterprise technology companies with $3-$20 million in revenue, structured as minority positions with active investor engagement.

2OA Collaborative (Operating Advisor Collaborative)
CategoryValue-Add Service Program
Description

Proprietary network of 45+ seasoned entrepreneurs and operating executives who actively engage portfolio companies on strategy, sourcing, board-level guidance, market intelligence, and acquisition target identification.

3Blue Heron Fund III
CategoryInvestment Fund
Description

Blue Heron Capital's third successive investment fund vehicle, with an investment committee that includes Operating Partner Jim Riley, used to deploy capital into healthcare and enterprise technology portfolio companies.

4OA Collaborative Membership Program
CategoryNetwork/Community Service
Description

Application-based membership program inviting experienced operators to join the OA Collaborative network, providing access to proprietary investment opportunities and the ability to engage with portfolio companies as advisors and mentors.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCore Operations DependencyTypeTechnology or Integration
Description

Blue Heron Capital uses Carta's platform (app.carta.com) for investor login and capital account management — a standard VC fund administration / cap table infrastructure relationship.

2Blue Heron Capital Active Portfolio Companies
Strategic tierFlagship — Full PortfolioTypeStrategic or Co-development Partner
Description

Blue Heron's active investments where the firm provides growth equity capital plus OA Collaborative human capital: Acclivity Health (Jacksonville, FL), AnswersNow (Richmond, VA), Authenticx (Indianapolis, IN), BlackCloak (Orlando, FL), Buildforce (Houston, TX), ChartSpan (Greenville, SC), Cookie Finance, Homecare.com/ShiftMed (McLean, VA), Kion (Fulton, MD), Mimecast (London, England), Motionworks (Atlanta, GA), Proof (Denver, CO), Redi Health (Columbus, OH), Remission Medical (2026), ShowdMe (New York, NY), Tava Health (Salt Lake City, UT), Vend Park (Boston, MA), Verato, VIDA (Coralville, IA), Yes Hearing (New York, NY).

blueheroncap.com
3Blue Heron Capital Exited Portfolio Companies
Strategic tierHistorical — Completed ExitsTypeStrategic or Co-development Partner
Description

Exited investments include Amwell (exited via IPO), Apogee IT Services (Sewickley, PA), Avizia (acquired by American Well), Aware, DuraMedic (acquired by AdaptHealth), PresenceLearning (acquired by Spectrum Equity & The Rise Fund), RevealRX (acquired by HealthPlan Data Solutions), STARC Systems (Brunswick, Maine — acquired by North Branch Capital), Stratasan (acquired by Syntellis), Tricast (acquired by Brown & Brown), Verisma (acquired by NewSpring Capital).

blueheroncap.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Healthcare-focused early-stage venture firm investing across care delivery, digital health, and health IT. Co-investor with Blue Heron in Tava Health Series B and directly comparable at Series A/B healthcare stage.

TypeDirect peer
Description

Boston-based early-stage growth equity firm investing in healthcare IT, healthcare services, and enterprise technology companies at similar revenue stages. Most directly comparable to Blue Heron in fund size, vertical focus, and active-investor model.

3Edison Partners
TypeDirect peer
Description

Princeton-based growth equity firm investing in high-growth technology-enabled services and healthcare companies. Comparable in check size, stage, and active-investor approach with sector specialization similar to Blue Heron's thesis.

TypeDirect peer
Description

New York-based growth equity firm focused on lower middle-market software, healthcare IT, and business services. Direct co-investor with Blue Heron in Tava Health and comparable in stage and sector focus.

TypeDirect peer
Description

Growth equity firm focused on high-growth, capital-efficient businesses in financial and business services. Direct co-investor with Blue Heron in Proof ($30.4M Series B led by Long Ridge) at overlapping stage and active-investor model.

TypeBroad incumbent
Description

The dedicated healthcare growth equity arm of UnitedHealth Group/Optum, investing broadly across digital health, care delivery, and health tech. Larger and better-capitalized competitor targeting the same healthcare thesis that dominates Blue Heron's portfolio.

TypeBroad incumbent
Description

Large global growth equity investor with deep healthcare and technology franchises. Competes for the same enterprise tech and healthcare growth-stage opportunities as Blue Heron but at materially larger check sizes and follow-on capacity.

TypeBroad incumbent
Description

Established venture and growth equity firm with healthcare and technology as two of its largest investment pillars. Competes for similar Series A/B opportunities in Blue Heron's verticals with a longer track record and broader LP base.

TypeEmerging player
Description

Healthcare-focused growth equity platform formed by Cambia Health Solutions and Mosaic Health Solutions. Direct healthcare overlap with Blue Heron's portfolio with smaller fund size and emerging deal flow.

TypeEmerging player
Description

Healthcare-dedicated growth equity firm investing in healthcare IT, services, and technology-enabled care delivery. Comparable in vertical focus and growth-stage orientation though narrower sector mandate than Blue Heron's enterprise tech exposure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries22 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment43 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Blue Heron Capital

Growth Equity / Venture Capitalblueheroncap.com

Blue Heron Capital is a Richmond, VA-based private growth equity firm investing minority positions in healthcare and enterprise technology companies at $3–$20 million revenue, pairing financial capital with its 45-member OA Collaborative of operating advisors to actively support portfolio CEOs through exit.

What Blue Heron Capital does

Blue Heron Capital is a private early-stage growth equity firm headquartered in Richmond, Virginia, founded in 2006 with first disclosed portfolio activity in 2013. The firm invests growth equity and minority positions in healthcare technology and services businesses and select enterprise technology platforms, targeting companies at the $3–$20 million revenue stage with high growth, strong gross margins, capital efficiency, and experienced management teams open to active investor engagement.

The firm's central differentiated product is the OA Collaborative — a network of 45+ Operating Advisors (seasoned entrepreneurs and operating executives) that supplements Blue Heron's 8-person core investment team. This network actively sources deals, contributes diligence, and engages with portfolio companies across strategy, talent, and execution. The OA Collaborative is positioned as "human capital" paired with financial capital and is the firm's primary mechanism for portfolio value creation. Co-founders Tom Benedetti and Andrew Tichenor, each with 30+ years of relevant experience, anchor the firm alongside Operating Partner Jim Riley, who brings a documented track record (5.8x average MOIC across 7 VC/PE-backed companies, $2B cumulative enterprise value at exit).

Blue Heron generates revenue through standard VC economics: management fees on committed and invested capital across at least three successive funds (Fund I, II, III), and carried interest from exits including Verisma (6.9x MOIC, 40% IRR), Stratasan (3.3x MOIC, 53% IRR), STARC Systems (38% CAGR during hold), Avizia (acquired by Amwell), and Amwell (IPO). The firm manages 20+ active and 12+ exited portfolio companies, with deal flow sourced through OA Collaborative referrals, direct CEO relationships, and co-investor networks (Catalyst Investors, Long Ridge, Nuveen, Peterson Partners, Toba Capital, SpringTide, Communitas Capital). Underlying technology is minimal — investor portal and cap table administration run on Carta, with no proprietary investment platform disclosed.

Blue Heron Capital firmographics

Firmographics
Name
Blue Heron Capital
Legal name
Blue Heron Capital
Website
https://blueheroncap.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Blue Heron Capital is a Richmond, VA-based private growth equity firm investing minority positions in healthcare and enterprise technology companies at $3–$20 million revenue, pairing financial capital with its 45-member OA Collaborative of operating advisors to actively support portfolio CEOs through exit.
Ownership category
akta.pro rank

Where Blue Heron Capital is headquartered

Location

Headquarters

HQ city
Richmond
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Blue Heron Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Management Fees & Carried Interest: As a growth equity / venture capital firm operating multiple funds (Fund I, Fund II, Fund III referenced), Blue Heron Capital generates revenue through typical VC economics: management fees on committed/invested capital across portfolio funds and carried interest on successful exits. Historical exits include Verisma (6.9X MOIC, 40% IRR), Stratasan (3.3X MOIC, 53% IRR), STARC Systems, Avizia (sold to American Well), Verima, Amwell (exited via IPO), and others.
  2. Capital Gains from Portfolio Exits: Returns generated from successful exits of portfolio company investments across healthcare and enterprise technology — including acquisitions by strategic buyers (American Well for Avizia, AdaptHealth for DuraMedic, Spectrum Equity/Rise Fund for PresenceLearning, Brown & Brown for Tricast, NewSpring Capital for Verisma, Syntellis for Stratasan, North Branch Capital for STARC Systems) and IPOs (Amwell).

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Blue Heron Capital product offering

Product offering

Core offering

Blue Heron Capital is an early-stage growth equity firm that makes minority investments in healthcare technology and services businesses and select enterprise technology platforms with $3-$20 million in revenue. Each investment is paired with access to the firm's OA Collaborative, a 45+ member network of operating advisors and seasoned entrepreneurs who provide portfolio companies with hands-on mentorship, board representation, sourcing, and strategic guidance. The firm manages multiple successive funds (Fund I, Fund II, Fund III) that deploy capital via typical VC economics of management fees and carried interest.

Product overview

Blue Heron Capital operates a single integrated service platform centered on early-stage growth equity investing combined with its proprietary OA Collaborative support program. The Growth Equity Investment Program constitutes the core offering, investing in healthcare (technology-based and services businesses addressing cost containment, patient experience, better care, technology innovation, and aging in place) and enterprise technology (B2B platforms with high switching costs, attractive growth, scalable technology, and potential healthcare applications). The OA Collaborative is the differentiated value-add layer that wraps every investment: an in-house network of operating advisors and seasoned entrepreneurs providing hands-on mentorship, market insight, sourcing, board representation, and strategic guidance to portfolio CEOs across the investment life cycle. Blue Heron Fund III is the current fund vehicle that deploys capital sourced through this platform. Together, these two elements (capital + human capital OA Collaborative) form a unified platform-plus-services architecture rather than a modular software product.

Differentiator

Problem solved

Functional benefit

Brands

  • OA Collaborative: An extensive network of seasoned professionals and successful entrepreneurs (Operating Advisors) who engage with portfolio companies in leadership, insight, and networking to accelerate their growth.

Products and services

  • Growth Equity Investment Program Early-stage growth equity investment program targeting healthcare and select enterprise technology companies with $3-$20 million in revenue, structured as minority positions with active investor engagement.
  • OA Collaborative (Operating Advisor Collaborative) Proprietary network of 45+ seasoned entrepreneurs and operating executives who actively engage portfolio companies on strategy, sourcing, board-level guidance, market intelligence, and acquisition target identification.
  • Blue Heron Fund III Blue Heron Capital's third successive investment fund vehicle, with an investment committee that includes Operating Partner Jim Riley, used to deploy capital into healthcare and enterprise technology portfolio companies.
  • OA Collaborative Membership Program Application-based membership program inviting experienced operators to join the OA Collaborative network, providing access to proprietary investment opportunities and the ability to engage with portfolio companies as advisors and mentors.

Quantifiable outcome

  • 5.8x average MOIC across 7 VC/PE-backed companies Jim Riley was involved with
  • +4 more outcomes

Companies that use Blue Heron Capital

Customer profile

Segments3 records

Ideal customer profiles2 records

Blue Heron Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Blue Heron Capital partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core operations dependency, flagship — full portfolio and historical — completed exits.

  • Carta (Investor Portal Technology)core operations dependencyTechnology or IntegrationBlue Heron Capital uses Carta's platform (app.carta.com) for investor login and capital account management — a standard VC fund administration / cap table infrastructure relationship.
  • Blue Heron Capital Active Portfolio Companiesflagship — full portfolioStrategic or Co-development PartnerBlue Heron's active investments where the firm provides growth equity capital plus OA Collaborative human capital: Acclivity Health (Jacksonville, FL), AnswersNow (Richmond, VA), Authenticx (Indianapolis, IN), BlackCloak (Orlando, FL), Buildforce (Houston, TX), ChartSpan (Greenville, SC), Cookie Finance, Homecare.com/ShiftMed (McLean, VA), Kion (Fulton, MD), Mimecast (London, England), Motionworks (Atlanta, GA), Proof (Denver, CO), Redi Health (Columbus, OH), Remission Medical (2026), ShowdMe (New York, NY), Tava Health (Salt Lake City, UT), Vend Park (Boston, MA), Verato, VIDA (Coralville, IA), Yes Hearing (New York, NY).
  • Blue Heron Capital Exited Portfolio Companieshistorical — completed exitsStrategic or Co-development PartnerExited investments include Amwell (exited via IPO), Apogee IT Services (Sewickley, PA), Avizia (acquired by American Well), Aware, DuraMedic (acquired by AdaptHealth), PresenceLearning (acquired by Spectrum Equity & The Rise Fund), RevealRX (acquired by HealthPlan Data Solutions), STARC Systems (Brunswick, Maine — acquired by North Branch Capital), Stratasan (acquired by Syntellis), Tricast (acquired by Brown & Brown), Verisma (acquired by NewSpring Capital).

Scale indicators13 records

Recent moves9 records

Expansion highlights5 records

Blue Heron Capital competitors and assessment

Company assessment

Emerging players

  • SpringTide Ventures: Healthcare-focused early-stage venture firm investing across care delivery, digital health, and health IT. Co-investor with Blue Heron in Tava Health Series B and directly comparable at Series A/B healthcare stage.
  • Echo Health Ventures: Healthcare-focused growth equity platform formed by Cambia Health Solutions and Mosaic Health Solutions. Direct healthcare overlap with Blue Heron's portfolio with smaller fund size and emerging deal flow.
  • Health Catalyst Capital: Healthcare-dedicated growth equity firm investing in healthcare IT, services, and technology-enabled care delivery. Comparable in vertical focus and growth-stage orientation though narrower sector mandate than Blue Heron's enterprise tech exposure.

Direct peers

  • .406 Ventures: Boston-based early-stage growth equity firm investing in healthcare IT, healthcare services, and enterprise technology companies at similar revenue stages. Most directly comparable to Blue Heron in fund size, vertical focus, and active-investor model.
  • Edison Partners: Princeton-based growth equity firm investing in high-growth technology-enabled services and healthcare companies. Comparable in check size, stage, and active-investor approach with sector specialization similar to Blue Heron's thesis.
  • Catalyst Investors: New York-based growth equity firm focused on lower middle-market software, healthcare IT, and business services. Direct co-investor with Blue Heron in Tava Health and comparable in stage and sector focus.
  • Long Ridge Equity Partners: Growth equity firm focused on high-growth, capital-efficient businesses in financial and business services. Direct co-investor with Blue Heron in Proof ($30.4M Series B led by Long Ridge) at overlapping stage and active-investor model.

Broad incumbents

  • Optum Ventures: The dedicated healthcare growth equity arm of UnitedHealth Group/Optum, investing broadly across digital health, care delivery, and health tech. Larger and better-capitalized competitor targeting the same healthcare thesis that dominates Blue Heron's portfolio.
  • General Atlantic: Large global growth equity investor with deep healthcare and technology franchises. Competes for the same enterprise tech and healthcare growth-stage opportunities as Blue Heron but at materially larger check sizes and follow-on capacity.
  • Norwest Venture Partners: Established venture and growth equity firm with healthcare and technology as two of its largest investment pillars. Competes for similar Series A/B opportunities in Blue Heron's verticals with a longer track record and broader LP base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Blue Heron Capital social profiles

Digital presence

Blue Heron Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Blue Heron Capital leadership team

Management profile

Number of profiles

Profiles11 records

Blue Heron Capital subsidiaries and ownership

Company hierarchy

Subsidiaries22 records

Blue Heron Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Blue Heron Capital M&A and investment

M&A and investment

M&A

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Blue Heron Capital

What does Blue Heron Capital do?

Blue Heron Capital is an early-stage growth equity firm that makes minority investments in healthcare technology and services businesses and select enterprise technology platforms with $3-$20 million in revenue. Each investment is paired with access to the firm's OA Collaborative, a 45+ member network of operating advisors and seasoned entrepreneurs who provide portfolio companies with hands-on mentorship, board representation, sourcing, and strategic guidance. The firm manages multiple successive funds (Fund I, Fund II, Fund III) that deploy capital via typical VC economics of management fees and carried interest.

Is Blue Heron Capital a public or private company?

Blue Heron Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Blue Heron Capital founded?

Blue Heron Capital was founded in 2013. It employs 11 to 50 people.

Where is Blue Heron Capital based?

Blue Heron Capital is headquartered in Richmond, United States, in the North America region.

How does Blue Heron Capital make money?

Two revenue lines are on record. Management Fees & Carried Interest is the primary driver. The others are capital Gains from Portfolio Exits.

Who are Blue Heron Capital's main competitors?

Emerging players on record are SpringTide Ventures, Echo Health Ventures and Health Catalyst Capital. Direct peers are .406 Ventures, Edison Partners, Catalyst Investors and Long Ridge Equity Partners. Broad incumbents are Optum Ventures, General Atlantic and Norwest Venture Partners.

Does Blue Heron Capital have an API?

No public API is recorded for Blue Heron Capital.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsBuildforce Raises $10M in Series A FundingBuildforce, a Houston-based electrician staffing platform, raised $10M in Series A financing led by Saepio Capital. The company will use the funds to accelerate national expansion and develop its technology for electricians and contractors. It has logged over 2 million work hours across more than 2,000 commercial projects.MorningstarBuildforce Raises $10M Series A to Staff Electricians NationallyBuildforce raised $10 million in Series A funding led by Saepio Capital, with participation from Blue Heron Capital and existing investors. The capital will fund national expansion and technology development for its electrician staffing platform. The company reports over 2 million logged hours across 2,000 commercial projects.EIN PresswireOgnomy Sleep Raises $20M Series A to Expand AI-Enabled Sleep Apnea CareOgnomy Sleep closed a $20 million Series A led by Catalyst Investors, with participation from Blue Heron Capital and others. The company has completed over 85,000 virtual visits nationwide and will use the funds to expand its AI-enabled platform and wearable integrations.Longevity.TechnologyRemission Medical closes Series A to expand virtual rheumatologyRemission Medical closed a Series A led by Blue Heron Capital to expand virtual rheumatology partnerships across U.S. health systems. The funding will grow its partner network, recruit clinical staff, and scale infrastructure, with major partners including Sentara and OrthoVirginia. The company plans to move into adjacent specialties in coming months.AijournRemission Medical Closes Series A Led by Blue Heron Capital to Expand Virtual Rheumatology Partnerships Across U.S. Health SystemsRemission Medical, a virtual rheumatology platform that embeds specialty care within health systems, closed a Series A funding round led by Blue Heron Capital to fuel network expansion, grow its clinical workforce, and scale its AI-native platform RemissionOS. The company currently operates across major health system partners including Sentara, OrthoVirginia, WellSpan, Ochsner, Campbell Clinic, Gundersen, MultiCare, and St. Francis, having achieved triple-digit growth over multiple years. The investment will also support expansion beyond rheumatology into adjacent specialties, with the company planning to announce initial steps in coming months.PR NewswireRemission Medical Closes Series A Led by Blue Heron Capital to Expand Virtual Rheumatology Partnerships Across U.S. Health SystemsRemission Medical, a virtual rheumatology company that embeds specialty care within health systems through a partnership model and AI-native workforce platform called RemissionOS, has closed a Series A funding round led by Blue Heron Capital. The investment will be used to expand the company's health system partner network, grow its clinical workforce, and scale infrastructure to deploy rheumatology access across additional markets, with plans to expand into adjacent specialties beyond rheumatology. The company currently operates with major health system partners including Sentara, WellSpan, and Ochsner, and has achieved triple-digit growth over multiple years.Venture Capital Access OnlineRemission Medical Closes Series A Led by Blue Heron Capital to Expand Virtual Rheumatology Partnerships Across U.S. Health SystemsRemission Medical closed a Series A led by Blue Heron Capital to expand its virtual rheumatology partnerships across U.S. health systems. The company embeds rheumatology care via its AI-native platform, RemissionOS, and plans to scale into adjacent specialties.TechStartupsCritical Loop raises $26M to cut power connection delays from years to days with modular microgridsCritical Loop raised $26 million in a Series A led by Conifer Infrastructure Partners and Hanover, bringing total funding to $49 million. The startup's modular microgrids aim to cut power connection delays from years to days. It plans to expand beyond California, where grid congestion is acute.TechStartupsTop Startup and Tech Funding News – April 13 2025On April 13, 2026, multiple startups raised funding across AI, energy, and healthcare. Slate Auto raised $650M Series C for EV trucks, ShengShu Technology raised RMB 2B for video generation, and Neomorph raised $100M for oncology R&D. The rounds reflect investor focus on infrastructure-heavy bets in AI, energy, and manufacturing.TechStartupsMicrosoft plans new Copilot features inspired by OpenClawMicrosoft is developing new Copilot features inspired by the open-source OpenClaw agent, with a team led by Omar Shahine exploring always-on agents. The initiative may be showcased at Build 2026, aiming to make Copilot a proactive assistant that works 24/7. Security concerns remain, but Microsoft is leveraging its infrastructure to make the approach viable at scale.